RAB39B and diffuse large B-cell lymphoma: As shown in Figure 7A and Supplementary Table S6, RAB39B was negatively correlated with the sensitivity to several chemotherapeutic drugs commonly used in DLBCL, like dexamethasone (r = −0.20, FDR = 1.22 × 10−6), doxorubicin (r = −0.30, FDR = 2.36 × 10−17), etoposide (r = −0.33, FDR = 4.12 × 10−21), vincristine (r = −0.38, FDR = 2.64 × 10−27), and cytarabine (r = −0.34, FDR = 1.12 × 10−21).